Provided by Tiger Fintech (Singapore) Pte. Ltd.

Voyager Therapeutics

3.51
-0.0750-2.09%
Volume:5.25K
Turnover:18.47K
Market Cap:193.78M
PE:-3.11
High:3.55
Open:3.52
Low:3.49
Close:3.59
Loading ...

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

GlobeNewswire
·
Yesterday

Voyager Therapeutics Inc (VYGR) Q4 2024 Earnings Call Highlights: Strong Financial Position and ...

GuruFocus.com
·
22 Apr

Promising Developments in Alzheimer’s Treatments Support Buy Rating for Voyager Therapeutics

TIPRANKS
·
10 Apr

Voyager Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
09 Apr

Promising Developments in Voyager Therapeutics’ Alzheimer’s Programs Highlight Potential of Dual Tau-Targeted Therapies

TIPRANKS
·
09 Apr

TD Cowen Keeps Their Buy Rating on Voyager Therapeutics (VYGR)

TIPRANKS
·
08 Apr

Top Executives Unload Thousands of Voyager Therapeutics Shares!

TIPRANKS
·
05 Apr

Voyager Therapeutics announces new data from two preclinical programs

TIPRANKS
·
31 Mar

Analysts Have Conflicting Sentiments on These Healthcare Companies: Teleflex (TFX) and Voyager Therapeutics (VYGR)

TIPRANKS
·
17 Mar

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Labcorp Holdings (LH) and Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
17 Mar

Voyager Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
14 Mar

Voyager Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Mar

Voyager Therapeutics: Strong Buy Rating Backed by Strategic Partnerships and Promising Pipeline

TIPRANKS
·
13 Mar

Voyager Therapeutics: Strong Financials and Promising Pipeline Drive Buy Rating

TIPRANKS
·
12 Mar

Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
12 Mar

Voyager Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
12 Mar

Voyager Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
12 Mar

Voyager Therapeutics reports Q4 EPS (59c), consensus (35c)

TIPRANKS
·
12 Mar

Voyager Therapeutics Q4 2024 GAAP EPS $(0.59) Misses $(0.38) Estimate, Sales $6.278M Miss $16.577M Estimate

Benzinga
·
12 Mar

Voyager Therapeutics Inc: Sees to Meet Planned Oper Expenses and Capex Needs Into Mid-2027

THOMSON REUTERS
·
12 Mar